Annibale Versari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Annibale Versari has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Salvarani
Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
8 shared publications - Nicolò Pipitone
Rheumatology Unit, Department of Internal Medicine, Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy.
7 shared publications - Francesco Muratore
Rheumatology Unit, Azienda Unitá Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy
2 shared publications - Gianluigi Bajocchi
Unita Operativa di Reumatologia, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
2 shared publications Luca Magnani
2 shared publicationsLuigi Boiardi
2 shared publications
Latest Publications
- 18 November 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 44 (2) , 247-248
Do we need FDG-PET/CT to assess atherosclerosis?
- 18 November 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 44 (2) , 247-248
Do we need FDG-PET/CT to assess atherosclerosis?
- Open Access
- 6 September 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (9) , 1480
Affinity of nat/68Ga-Labelled Curcumin and Curcuminoid Complexes for β-Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers
Curcumin derivatives labelled with fluorine-18 or technetium-99m have recently shown their potential as diagnostic tools for Alzheimer’s disease. Nevertheless, no study by exploiting the labelling with gallium-68 has been performed so far, in spite of its suitable properties (positron emitter, generator produced radionuclide). Herein, an evaluation of the affinity for synthetic β-amyloid fibrils and for amyloid plaques of three nat/68Ga-labelled curcumin analogues, namely curcumin curcumin (CUR), bis-dehydroxy-curcumin (bDHC) and diacetyl-curcumin (DAC), was performed. Affinity and specificity were tested in vitro on amyloid synthetic fibrils by using gallium-68 labelled compounds. Post-mortem brain cryosections from Tg2576 mice were used for the ex vivo visualization of amyloid plaques. The affinity of 68Ga(CUR)2+, 68Ga(DAC)2+, and 68Ga(bDHC)2+ for synthetic β-amyloid fibrils was moderate and their uptake could be observed in vitro. On the other hand, amyloid plaques could not be visualized on brain sections of Tg2576 mice after injection, probably due to the low stability of the complexes in vivo and of a hampered passage through the blood–brain barrier. Like curcumin, all nat/68Ga-curcuminoid complexes maintain a high affinity for β-amyloid plaques. However, structural modifications are still needed to improve their applicability as radiotracers in vivo.
- 6 September 2016
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (9) , 1480
Open AccessAffinity of nat/68Ga-Labelled Curcumin and Curcuminoid Complexes for β-Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers
Curcumin derivatives labelled with fluorine-18 or technetium-99m have recently shown their potential as diagnostic tools for Alzheimer’s disease. Nevertheless, no study by exploiting the labelling with gallium-68 has been performed so far, in spite of its suitable properties (positron emitter, generator produced radionuclide). Herein, an evaluation of the affinity for synthetic β-amyloid fibrils and for amyloid plaques of three nat/68Ga-labelled curcumin analogues, namely curcumin curcumin (CUR), bis-dehydroxy-curcumin (bDHC) and diacetyl-curcumin (DAC), was performed. Affinity and specificity were tested in vitro on amyloid synthetic fibrils by using gallium-68 labelled compounds. Post-mortem brain cryosections from Tg2576 mice were used for the ex vivo visualization of amyloid plaques. The affinity of 68Ga(CUR)2+, 68Ga(DAC)2+, and 68Ga(bDHC)2+ for synthetic β-amyloid fibrils was moderate and their uptake could be observed in vitro. On the other hand, amyloid plaques could not be visualized on brain sections of Tg2576 mice after injection, probably due to the low stability of the complexes in vivo and of a hampered passage through the blood–brain barrier. Like curcumin, all nat/68Ga-curcuminoid complexes maintain a high affinity for β-amyloid plaques. However, structural modifications are still needed to improve their applicability as radiotracers in vivo.
- 12 June 2015
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 42 (9) , 1339-40
Adding variables to complexity. Molecular imaging and molecular biology: a no-longer-secret liaison in NETs.
- 12 June 2015
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 42 (9) , 1339-40
Adding variables to complexity. Molecular imaging and molecular biology: a no-longer-secret liaison in NETs.
- Open Access
- 20 July 2014
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 37 (9) , 875-909
Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
- 20 July 2014
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 37 (9) , 875-909
Open AccessItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms
- 1 October 2013
- Published by Oxford University Press (OUP)
- p. 1113-1124
Large-vessel vasculitis
- 1 January 2013
- Published by Springer Nature
- p. 289-331
Nuclear Medicine Imaging in Chronic Inflammatory Diseases
- 1 January 2013
- Published by Springer Nature
- p. 289-331
Nuclear Medicine Imaging in Chronic Inflammatory Diseases
- 1 January 2013
- Published by Springer Nature
- p. 1-22
Normal Findings from Different Radiopharmaceuticals and Techniques, with Variants and Pitfalls
- 1 January 2013
- Published by Springer Nature
- p. 1-22
Normal Findings from Different Radiopharmaceuticals and Techniques, with Variants and Pitfalls
- 17 October 2012
- Vol. 30 (5) , 776-8
Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis.
Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mg/kg/bodyweight at week 0, 2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18FFluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.
- 17 October 2012
- Vol. 30 (5) , 776-8
Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis.
Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis (IRF). However, relapses are frequent upon tapering of the glucocorticoid dose. A variety of traditional immunosuppressants have been proposed as steroid-sparing agents, but some patients fail to adequately respond to combined glucocorticoid and immunosuppressive therapy. We report a patient with IRF refractory to combined glucocorticoid and methotrexate therapy treated with the anti-TNF-α monoclonal antibody infliximab. Infliximab was administered at 5 mg/kg/bodyweight at week 0, 2, 6 and 8-weekly thereafter for 3 consecutive years. Drug efficacy and safety were assessed clinically and by laboratory tests at treatment onset and subsequently before each infusion. In addition, 18FFluorodeoxyglucose (FDG) positron emission computerised tomography (PET/CT) and abdominal CT scans were used to monitor disease activity and response to treatment. Infliximab therapy resulted in a satisfactory clinical and laboratory response paralleled by an improvement in imaging findings. No serious adverse events were noted. Infliximab may be an effective and safe treatment for refractory IRF. A controlled study is required to confirm our findings.